Journal: Immunity

Article Title: Signaling through the inhibitory Fc receptor FcγRIIB induces CD8 T cell apoptosis to limit T cell immunity

doi: 10.1016/j.immuni.2019.12.006

Figure Lengend Snippet: KEY RESOURCES TABLE

Article Snippet: Dr. Mark Cragg InVivoMAb anti-mouse CD16/32 (clone 2.4G2) BioXcell Cat# BE0307, RRID:AB_2736987 Bacterial and Virus Strains Biological Samples Emory Transplant Center Biorepository Emory IRB protocol #00046593 Chemicals, Peptides, and Recombinant Proteins GolgiPlug BD Biosciences Cat# 555029 OVA peptide 257–264 (SIINFEKL) GenScript Cat# RP10611 CTLA-4Ig (abatacept) Bristol-Myers Squibb, Abatacept (Orencia) Anti-CD28 domain antibodies Bristol-Myers Squibb Collagenase (type 1A) Sigma-Aldrich C2654 Hyaluronidase (type 1) Sigma-Aldrich H3506 Collagenase P Sigma-Aldrich Ref# 11213865001 Collagenase D Sigma-Aldrich Ref# 1088866001 Recombinant Fgl2 R&D Systems R&D Cat# 5257-FL-050 Critical Commercial Assays MACS CD8a+ T cell isolation kit, mouse Miltenyi Biotec 130-104-075 Quick-RNA MicroPrep Kit Zyma Research R1051 SMART-seq v4 cDNA synthesis kit Takara Cat# 634894 NexteraXT kit Illumina FC-131–1096 Mouse Fgl2 ELISA Biolegend Biolegend Cat# 437807 RNeasy Plus Micro Kit Qiagen Qiagen Cat# 74034 High Capacity cDNA reverse transcription kit ThermoFisher ThermoFisher Cat# 4368814 HT HG-U133 Plus PM BeadChip Affymetrix Thermo Fisher Cat# 901261 Lightning Link R-PE Antibody Labeling kit Novus Biologicals Cat # 703–0010 CountBright Beads Life Technologies Cat # C36950 Deposited Data RNAseq data NCBI Gene Expression Omnibus (GEO) GSE118439 Experimental Models: Cell Lines B16 Melanoma-OVA Brown, et al., 2001 , provided by Dr. Yang-Xin Fu Experimental Models: Organisms/Strains NCI C57Bl/6Ncr (NCI grantee program) Charles River Stock #556 NCI B6-LY5.1/Cr (NCI grantee program) Charles River Stock #564 OT-I Hogquist et al., 1994 OT-II Barnden et al., 1998 mOVA (C57Bl/6 background, H-2b) Ehst et al., 2013 Dr. Marc Jenkins B6.129P2-Aicda tm1(cre)Mnz /J ( Aicda −/− ) The Jackson Laboratory Stock #007770 B6;129S-Fcgr2btm1Ttk/J ( Fcgr2b −/− ) The Jackson Laboratory Stock #002848 EM:06078 Fcgr2b Fcgr2bB6null B6(Cg)-Fcgr2btm12Sjv/Cnbc ( Fcgr2b −/− ) European Mutant Mouse Archive; Dr. J.S.

Techniques: Control, Virus, Recombinant, Cell Isolation, cDNA Synthesis, Enzyme-linked Immunosorbent Assay, Reverse Transcription, Antibody Labeling, Gene Expression, Mutagenesis, Software

Journal: Clinical Cancer Research

Article Title: Expression and Functional Role of CCR9 in Prostate Cancer Cell Migration and Invasion

doi: 10.1158/1078-0432.ccr-04-0266

Figure Lengend Snippet: Fig. 2 Changes in CCR9-positive prostate cell populations. In confir- mation of RT-PCR analysis of CCR9 mRNA expression, LNCaP, PC3, and normal PrEC prostatic cells were stained with PE-conjugated iso- type control or anti-CCR9 monoclonal antibodies and quantified, in triplicate, by flow cytometry. The percentage of positive CCR9 surface expression by LNCaP, PC3, or PrEC cells was repeated three times; representative histograms are shown.

Article Snippet: Phycoerythrin (PE)-conjugated mouse antihuman CCR9 (clone 12G5) antibody was purchased from R&D Systems (Minneapolis, MN).

Techniques: Reverse Transcription Polymerase Chain Reaction, Expressing, Staining, Control, Bioprocessing, Flow Cytometry

Journal: Clinical Cancer Research

Article Title: Expression and Functional Role of CCR9 in Prostate Cancer Cell Migration and Invasion

doi: 10.1158/1078-0432.ccr-04-0266

Figure Lengend Snippet: Fig. 1 CCR9 mRNA expressed by prostate cancer and normal epithe- lial cells. Total RNA was isolated from prostate cancer cell lines LNCaP (f) and PC3 () as well as from normal PrEC cells (p). Quantitative RT-PCR analysis of CCR9 mRNA expression was performed in tripli- cate. The copies of transcripts are expressed relative to actual copies of 18S rRNA SE. Asterisks indicate statistical significance (P 0.05) between normal and cancer cells (x) and between LNCaP and PC3 cells ().

Article Snippet: Phycoerythrin (PE)-conjugated mouse antihuman CCR9 (clone 12G5) antibody was purchased from R&D Systems (Minneapolis, MN).

Techniques: Isolation, Quantitative RT-PCR, Expressing

Journal: Clinical Cancer Research

Article Title: Expression and Functional Role of CCR9 in Prostate Cancer Cell Migration and Invasion

doi: 10.1158/1078-0432.ccr-04-0266

Figure Lengend Snippet: Fig. 4 CCR9-mediated prostate cancer cell invasion. LNCaP, PC3, and PrEC cells were tested for their ability to invade or translocate across a Matrigel matrix in response to chemotactic gradients of 0 ng/mL CCL25 (), 100 ng/mL CCL25 ( ), or 100 ng/mL CCL25 1 g/mL anti- CCR9 monoclonal antibody (f) in the lower chamber. Asterisks indicate significant differences (P 0.05) between no additions and CCL25- treated cells ().

Article Snippet: Phycoerythrin (PE)-conjugated mouse antihuman CCR9 (clone 12G5) antibody was purchased from R&D Systems (Minneapolis, MN).

Techniques:

Journal: Clinical Cancer Research

Article Title: Expression and Functional Role of CCR9 in Prostate Cancer Cell Migration and Invasion

doi: 10.1158/1078-0432.ccr-04-0266

Figure Lengend Snippet: Fig. 3 CCR9-mediated prostate cancer cell migration. LNCaP, PC3, and normal prostatic epithelial PrEC cells were tested for their ability to migrate to 0 ng/mL CCL25 , 100 ng/mL CCL25 , or 100 ng/mL of CCL25 1 g/mL anti-CCR9 monoclonal antibody f in the lower chamber. The number of cells (SE) that migrated to CCL25, of the initial 104 cells used to seed the migration chamber, are shown with asterisks that indicate significant differences (P 0.05) between no additions and CCL25-treated cells ().

Article Snippet: Phycoerythrin (PE)-conjugated mouse antihuman CCR9 (clone 12G5) antibody was purchased from R&D Systems (Minneapolis, MN).

Techniques: Migration